HomeCompareCLVLY vs FCPT

CLVLY vs FCPT: Dividend Comparison 2026

CLVLY yields 0.36% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLY wins by $256.4K in total portfolio value· pulled ahead in Year 8
10 years
CLVLY
CLVLY
● Live price
0.36%
Share price
$7.24
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$305.5K
Annual income
$199,327.02
Full CLVLY calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — CLVLY vs FCPT

📍 CLVLY pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLYFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLY + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLY pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLY
Annual income on $10K today (after 15% tax)
$30.66/yr
After 10yr DRIP, annual income (after tax)
$169,427.97/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, CLVLY beats the other by $164,518.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLY + FCPT for your $10,000?

CLVLY: 50%FCPT: 50%
100% FCPT50/50100% CLVLY
Portfolio after 10yr
$177.3K
Annual income
$102,551.15/yr
Blended yield
57.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

CLVLY
No analyst data
Altman Z
17.2
Piotroski
5/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLY buys
0
FCPT buys
0
No recent congressional trades found for CLVLY or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLYFCPT
Forward yield0.36%6.05%
Annual dividend / share$0.03$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%15.8%
Portfolio after 10y$305.5K$49.1K
Annual income after 10y$199,327.02$5,775.28
Total dividends collected$276.6K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CLVLY vs FCPT ($10,000, DRIP)

YearCLVLY PortfolioCLVLY Income/yrFCPT PortfolioFCPT Income/yrGap
1$10,772$72.13$11,401$700.92$629.00FCPT
2$11,671$145.24$13,064$864.84$1.4KFCPT
3$12,783$294.14$15,051$1,072.48$2.3KFCPT
4$14,279$602.13$17,442$1,337.22$3.2KFCPT
5$16,536$1,257.27$20,340$1,677.08$3.8KFCPT
6$20,415$2,721.45$23,880$2,116.57$3.5KFCPT
7$28,124$6,280.07$28,241$2,689.36$117.00FCPT
8← crossover$46,264$16,171.07$33,660$3,442.07+$12.6KCLVLY
9$99,224$49,721.74$40,456$4,439.95+$58.8KCLVLY
10$305,497$199,327.02$49,063$5,775.28+$256.4KCLVLY

CLVLY vs FCPT: Complete Analysis 2026

CLVLYStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLY Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this CLVLY vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLY vs SCHDCLVLY vs JEPICLVLY vs OCLVLY vs KOCLVLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.